Category: Caroline Redeker

  • Optimised clinical research through decentralised trials

    Not only did the COVID-19 pandemic bring lockdown rules and increased safety protocols, it also led to delays, reconfigurations, limited patient access, and other restrictions for life science research and development. However, one benefit is that it accelerated innovations underway to solve long-standing clinical process issues. “The pandemic turbo-charged trial decentralisation,” says Caroline Redeker, senior […]